BUZZ-Marinus down after seizure treatment fails to meet a key late-stage study goal

Reuters06-17

** Shares of drug maker Marinus Pharmaceuticals down 12.6% at $1.30 before the bell

** Co says its intravenous treatment, for a type of seizure known as refractory status epilepticus, failed to meet one of the two key goals, in a late stage study

** Miranus's drug ganaxolone, a neuroactive steroid, failed to achieve statistical significance on the second endpoint of the proportion of patients not progressing to intravenous anesthesia versus placebo

** The oral version of the drug, under the brand name Ztalmy, is approved by the U.S. FDA for treatment of seizures associated with CDKL5 deficiency disorder, a rare genetic epilepsy

** As of last close, stock down 86.5% YTD

(Reporting by Pratik Jain in Bengaluru)

((Pratik.Jain@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment